Amanta Healthcare IPO vs Denis Chem vs Zydus LIFE: How Healthcare Stocks Are Trading Ahead Of New IPO Listing

Amanta Healthcare IPO vs Denis Chem vs Zydus Lifescience: The much-awaited mainboard initial public offering (IPO) of Amanta Healthcare Limited opened for subscription on Monday, September 1.

As the Gujarat-headquartered pharma company is on track for BSE, NSE listing, let's understand where it stands against its peers like Zydus Lifescience and Denis Chem. We will also understand how these companies' stocks have performed since their IPO listing.

Amanta Healthcare IPO vs Denis Chem vs Zydus Lifesciences

Amanta Healthcare's market capitalisation post listing is expected to be Rs 489.25 crore, according to the Ventura report. Whereas, Denis Chem's market capitalisation stood at Rs 135.09 crore on BSE on Monday, September 1 at 2:50 pm. Zydus Lifesciences' market capitalisation stood at Rs 99,979.41 crore.

Considering Amanta Healthcare IPO grey market premium, the IPO may see a listing for Rs 151. According to investorgain.com, Amanta Healthcare IPO GMP Today stood at Rs 25 per share.

Denis Chem shares were trading 4.8% higher at Rs 97.35 per share on BSE with a market capitalisation of Rs 135.30 crore at 3 pm. Whereas, Zydus Lifesciences Limited shares were trading 1.22% higher at Rs 992.85 per share at 3 pm.

Amanta Healthcare IPO Subscription Status

Amanta Healthcare IPO has been subscribed to around 3.35 times till 2:54 pm on Monday, according to Chittorgarh.com. The issue has been subscribed to by around 5.06 times in the retail category and 3.82 times in the NII category. There was no participation registered in the QIB category till now.

Amanta Healthcare IPO GMP Today

Amanta Healthcare's last GMP stood at Rs 25, according to investorgain.com. With this the IPO is expected to be listed for Rs 126 (including the upper price band of Rs 126 and the latest GMP). The IPO may be listed with an expected percentage gain or loss per share of 19.84%. The IPO GMP today is close to Amanta Healthcare's highest IPO GMP of Rs 28.

Amanta Healthcare IPO: Should You Subscribe?

Ventura, in its note, has recommended investors to 'Subscribe' to Amanta Healthcare IPO. "A key unique selling proposition (USP) is their SteriPort brand for large volume parenterals (LVPs), which features a two-port design, enhancing patient safety and meeting market demands for IV fluid administration," noted Ventura in its report.

Brokerage 'Scoop Investment' has also recommended investors to 'Subscribe for Long Term' duration.

The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.